Physician profile
David E Mccune
NPI 1457366320
$2,610.30
in general payments reported to CMS, 2019-2025
39 companies · $1,540 in 2025
The $1,540 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $60.96 · 2023: $350 · 2024: $659 · 2025: $1,540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,533 · Education: $15.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,533.38 |
| Education | $15.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $254.57 | 2024-2025 | Enhertu, Lynparza, Tagrisso |
| Daiichi Sankyo INC. | $252.00 | 2024-2025 | Enhertu, Datroway |
| Abbvie INC. | $203.17 | 2024-2025 | |
| Janssen Biotech, INC. | $140.53 | 2023-2025 | Rybrevant, Darzalex, Tecvayli |
| Genzyme Corporation | $139.77 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $139.68 | 2023-2025 | Keytruda, Welireg, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $120.22 | 2023-2025 | Opdivo, Opdualag |
| Pharmacyclics LLC, An Abbvie Company | $110.91 | 2022-2023 | Imbruvica, Epkinly |
| Taiho Oncology, INC. | $94.16 | 2024-2025 | |
| Glaxosmithkline, LLC. | $81.69 | 2023-2025 | Jemperli, Ojjaara, Zejula |
| Stemline Therapeutics INC. | $76.21 | 2025 | Orserdu |
| Syndax Pharmaceuticals, INC. | $75.39 | 2025 | |
| Beigene USA, INC. | $73.78 | 2023-2025 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $73.42 | 2023-2025 | |
| Eisai INC. | $70.23 | 2022-2025 |
Show all 38 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$191,666.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mccune listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.